Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Mol Cell Neurosci. 2017 Feb 16;80:52–57. doi: 10.1016/j.mcn.2017.02.004

Figure 4. UCP2 is needed to oppose PA-induced upregulation of pro-inflammatory marker iNOS.

Figure 4

Pretreatment with HTS01037 attenuates PA-induced iNOS expression in BV2 microglia (p<0.001 PA vs. C, HTS, HTS+PA). In UCP2kd microglia, PA increases iNOS expression, however, HTS01037 is no longer able to attenuate PA-induced iNOS upregulation (p<0.05 C vs. HTS+PA, p<0.001 C vs. HTS, p<0.0001 C vs. PA, p<0.0001 PA vs. HTS, HTS+PA). Letters indicate significant differences between treatment groups.